
































	<p><b>Cristi Altman</b> Takeda Pharmaceutical (781) 460-7756 <a href="mailto:cristi.altman@takeda.com">cristi.altman@takeda.com</a> <b>TEAM # 6</b></p>		<p><b>Jennifer Avallone</b> Takeda Pharmaceutical (312) 622-4504 <a href="mailto:jennifer.avallone@takeda.com">jennifer.avallone@takeda.com</a> <b>TEAM # 2</b></p>		<p><b>Rajshree Balasubramanian</b> Fidelity Investments (617) 943-1360 <a href="mailto:rajshree.balasubramanian@fmr.com">rajshree.balasubramanian@fmr.com</a> <b>TEAM # 3</b></p>		<p><b>Japneet Bedi</b> Alkermes, Inc. (781) 472-0384 <a href="mailto:japneet.bedi@alkermes.com">japneet.bedi@alkermes.com</a> <b>TEAM # 2</b></p>
	<p><b>Kathleen Bentley</b> Fidelity Investments\ ( ) 168-3168 <a href="mailto:kathleen.bentley@fmr.com">kathleen.bentley@fmr.com</a> <b>TEAM # 5</b></p>		<p><b>Hannah Cummings</b> Alkermes, Inc. (781) 609-6376 <a href="mailto:hannah.cummings@alkermes.com">hannah.cummings@alkermes.com</a> <b>TEAM # 6</b></p>		<p><b>Ellen Doherty</b> BCBS of MA (617) 246-5803 <a href="mailto:ellen.doherty@bcbsma.com">ellen.doherty@bcbsma.com</a> <b>TEAM # 7</b></p>		<p><b>Margaret (Meg) Duncan</b> Vertex Pharmaceuticals (617) 961-0775 <a href="mailto:meg_duncan@vrtx.com">meg_duncan@vrtx.com</a> <b>TEAM # 8</b></p>
	<p><b>Sondra Fleming</b> New Balance, Inc. (617) 201-3540 <a href="mailto:Sunni.fleming@newbalance.com">Sunni.fleming@newbalance.com</a> <b>TEAM # 9</b></p>		<p><b>Melinda Hamel-Graziano</b> Fidelity Investments (617) 392-2544 <a href="mailto:melinda.hamel@fmr.com">melinda.hamel@fmr.com</a> <b>TEAM # 1</b></p>		<p><b>Natalie Hosea</b> Takeda Pharmaceutical (619) 930-8215 <a href="mailto:natalie.hosea@takeda.com">natalie.hosea@takeda.com</a> <b>TEAM # 4</b></p>		<p><b>Patricia Hunter</b> Fidelity Investments (603) 791-8695 <a href="mailto:Pat.hunter@fmr.com">Pat.hunter@fmr.com</a> <b>TEAM # 9</b></p>
	<p><b>Nicole Hurst</b> Vertex Pharmaceuticals (617) 961-7403 <a href="mailto:nicole_hurst@vrtx.com">nicole_hurst@vrtx.com</a> <b>TEAM # 1</b></p>		<p><b>China Izatt</b> Takeda Pharmaceutical (503) 849-3623 <a href="mailto:china.izatt@takeda.com">china.izatt@takeda.com</a> <b>TEAM # 9</b></p>		<p><b>Colleen Jones</b> Loomis, Sayles &amp; Co. (617) 535-5343 <a href="mailto:cjones@loomissayles.com">cjones@loomissayles.com</a> <b>TEAM # 4</b></p>		<p><b>Elizabeth (Beth) Kenneally</b> Takeda Pharmaceutical (781) 482-0689 <a href="mailto:Elizabeth.kenneally@takeda.com">Elizabeth.kenneally@takeda.com</a> <b>TEAM # 8</b></p>
	<p><b>Jessica Kessinger</b> Raytheon Technologies Corp. (978) 858-4264 <a href="mailto:jessica.kessinger@rtx.com">jessica.kessinger@rtx.com</a> <b>TEAM # 9</b></p>		<p><b>Swetha Krishnan</b> Alkermes, Inc. (781) 249-9295 <a href="mailto:swetha.krishnan@alkermes.com">swetha.krishnan@alkermes.com</a> <b>TEAM # 3</b></p>		<p><b>Carolyn Manis Sorensen</b> Fidelity Investments (801) 856-1377 <a href="mailto:carolyn.manissorensen@fmr.com">carolyn.manissorensen@fmr.com</a> <b>TEAM # 2</b></p>		<p><b>Barbara Moreau</b> Raytheon Technologies Corp. (508) 490-3431 <a href="mailto:barbara.moreau@rtx.com">barbara.moreau@rtx.com</a> <b>TEAM # 6</b></p>
	<p><b>Leah Moretti</b> BCBS of MA (617) 246-4426 <a href="mailto:leah.moretti@bcbsma.com">leah.moretti@bcbsma.com</a> <b>TEAM # 2</b></p>		<p><b>Jessica O'Keefe</b> Raytheon Technologies Corp. (339) 645-6624 <a href="mailto:jessica_l_cook@raytheon.com">jessica_l_cook@raytheon.com</a> <b>TEAM # 3</b></p>		<p><b>Chi Onyebuchi</b> Takeda Pharmaceutical (617) 588-8185 <a href="mailto:chi.onyebuchi@takeda.com">chi.onyebuchi@takeda.com</a> <b>TEAM # 5</b></p>		<p><b>Hemali Premji</b> Boehringer Ingelheim (203) 733-7158 <a href="mailto:hemali.premji@boehringer-ingelheim.com">hemali.premji@boehringer-ingelheim.com</a> <b>TEAM # 5</b></p>
	<p><b>Sarah Rosecrans</b> Boehringer Ingelheim (815) 315-3868 <a href="mailto:sarah.rosecrans@boehringer-ingelheim.com">sarah.rosecrans@boehringer-ingelheim.com</a> <b>TEAM # 3</b></p>		<p><b>Amy Sane</b> Raytheon Technologies Corp. (339) 223-8149 <a href="mailto:Amy.L.Sane@raytheon.com">Amy.L.Sane@raytheon.com</a> <b>TEAM # 5</b></p>		<p><b>Audrey Schaub</b> Fidelity Investments (603) 767-5846 <a href="mailto:audrey.caswell@fmr.com">audrey.caswell@fmr.com</a> <b>TEAM # 7</b></p>		<p><b>Jill Schuler</b> Vertex Pharmaceuticals (617) 680-8356 <a href="mailto:jill_schuler@vrtx.com">jill_schuler@vrtx.com</a> <b>TEAM # 6</b></p>
	<p><b>Cara Stockham</b> Raytheon Technologies Corp (240) 554-8103 <a href="mailto:cara.stockham@rtx.com">cara.stockham@rtx.com</a> <b>TEAM # 8</b></p>		<p><b>Lei Sun</b> Alkermes, Inc. (781) 609-6151 <a href="mailto:Lei.Sun@alkermes.com">Lei.Sun@alkermes.com</a> <b>TEAM # 4</b></p>		<p><b>Erin Walsh</b> Raytheon Technologies Corp. (978) 815-9286 <a href="mailto:erin.walsh@raytheon.com">erin.walsh@raytheon.com</a> <b>TEAM # 4</b></p>		<p><b>Ting Wang</b> Boehringer Ingelheim (203) 778-7603 <a href="mailto:ting_3.wang@boehringer-ingelheim.com">ting_3.wang@boehringer-ingelheim.com</a> <b>TEAM # 1</b></p>
	<p><b>Susan (Su) Wu</b> Vertex Pharmaceuticals (617) 961-7030 <a href="mailto:susan_wu@vrtx.com">susan_wu@vrtx.com</a> <b>TEAM # 7</b></p>		<p><b>Olga Zaharova</b> Loomis, Sayles &amp; Co. (339) 235-4831 <a href="mailto:ozaharova@loomissayles.com">ozaharova@loomissayles.com</a> <b>TEAM # 1</b></p>				